Home / Business and Economy / Promoter Stake Falls: Dilution or Smart Play?
Promoter Stake Falls: Dilution or Smart Play?
6 Aug
Summary
- Falling promoter stakes can mislead investors, masking corporate actions like share issues.
- Beta Drugs' sales grew 27% over five years, funded by capacity expansion.
- Suven Life Sciences is a research bet, valuing its pipeline over current earnings.
Promoter stake reductions in companies can be deceptive, often stemming from corporate actions like share issuances rather than genuine divestment. This was observed in two healthcare firms.
Beta Drugs Ltd., an oncology drug manufacturer, saw its promoter holding decrease significantly due to a preferential issue. Despite this, the company demonstrated strong financial performance, with sales growing 27% compounded annually between FY21 and FY26, alongside EBITDA growth.
In contrast, Suven Life Sciences Ltd., a clinical-stage biopharmaceutical firm, experienced a promoter stake drop primarily from warrant conversions. This dilution is part of its strategy to fund extensive research and development for neurodegenerative disorder treatments.
Retail investors are cautioned to look beyond simple percentage changes. Understanding corporate actions such as preferential issues or warrant conversions is crucial, as these events alter shareholding percentages without active trading.
Beta Drugs, valued at Rs 2,602 cr, is expanding its market presence. Suven Life, with a market cap of Rs 8,764 cr, is valued on its promising drug pipeline rather than current financial returns.
